Global biopharmaceutical company, Paris-listed Ipsen, has agreed to acquire ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. Under the terms of the agreement, shareholders of ImCheck Therapeutics will…
France: Ipsen to strengthen oncology pipeline with ImCheck Therapeutics
…
…






